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Introduction: Previously, we reported the frequency of epidermal 
growth factor receptor (EGFR) and KRAS mutations in nonsmall-
cell lung cancer (NSCLC) patients in Latin America. The EGFR 
mutation frequency was found between Asian (40%) and Caucasian 
(15%) populations. Here, we report the updated distribution of 
NSCLC mutations.
Methods: A total of 5738 samples from NSCLC patients from Argentina 
(1713), Mexico (1417), Colombia (1939), Peru (393), Panama (174), 
and Costa Rica (102) were genotyped for EGFR and KRAS.
Results: The median patient age was 62.2 ± 12.3 years; 53.5% 
were women, 46.7% had a history of smoking, and 95.2% had 
adenocarcinoma histology. The frequency of EGFR mutations was 
26.0% (95% confidence interval [CI], 24.9–27.1; Argentina, 14.4% 
[12.8–15.6]; México, 34.3% [31.9–36.7]; Colombia, 24.7% [22.8–
26.6]; Peru, 51.1% [46.2–55.9]; Panamá, 27.3 [20.7–33.9]; and Costa 
Rica, 31.4% [22.4–40.4]). The frequency of KRAS mutations was 
14.0% (9.1–18.9). In patients with adenocarcinoma, EGFR muta-
tions were independently associated with gender (30.7% females 
vs. 18.4% males; p < 0.001), nonsmoker status (27.4% vs. 17.1%, 
p < 0.001), ethnicity (mestizo/indigenous, 35.3% vs. Caucasian, 13.7%, 
p < 0.001), and the absence of KRAS mutation (38.1% vs. 4.7%; 
p < 0.001). The overall response rate to EGFR tyrosine kinase inhibi-
tors was 60.6% (95% CI, 52–69), with a median progression-free 
survival and overall survival of 15.9 (95% CI, 12.420.6) and 32 
months (95% CI, 26.5–37.6), respectively.
Conclusion: Our findings support the genetic heterogeneity of 
NSCLC in Latin America, confirming that the frequency of EGFR 
mutations is intermediate between that observed in the Asian and 
Caucasian populations.
Key Words: Non small-cell lung cancer, Epidermal growth factor, 
Anaplastic lymphoma kinase, Mutation, Frequency.
(J Thorac Oncol. 2015;10: 838–843)
Although the overall incidence of cancer is lower in Latin America (age-standardized rate of 163 per 100,000) 
than in Europe (264 per 100,000) or the United States (300 
per 100,000), the mortality burden is greater.1 Lung cancer 
is the main cause of cancer-related death in Latin America,2 
although different regional trends in cancer types exist.
The recognition of a subgroup of patients with nons-
mall-cell lung cancer (NSCLC) harboring mutations of the 
epidermal growth factor receptor (EGFR) gene that exhibit 
a favorable response to tyrosine kinase inhibitors (TKIs) has 
changed the way we view lung cancer over the last decade. The 
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90% of EGFR-activating mutations for lung cancer include the 
leucine-to-arginine substitution at position 858 (L858R) and 
deletions in exon 19.3–6 The EGFR T790M mutation, which 
has been reported at a low frequency in untreated patients 
with stage IIIB/IV NSCLC (5.8%), has been detected in ~50% 
of patients who become resistant to EGFR TKIs. The clas-
sical phenotype associated with EGFR-activating mutations 
includes female sex, Asian ethnicity, nonsmoker status, and 
adenocarcinoma histology. The precise prevalence of activat-
ing mutations has been reported in different populations: 15% 
in patients from North America and Europe, 40% in patients 
from East Asia, 15% to 20% in African Americans patients, 
and 20% to 25% in patients from the Indian subcontinent.7–11 
Previously, we reported that the frequency of EGFR mutation 
was 33.2% in 1150 patients from Latin America (Argentina, 
19.1%; Mexico, 31.2%; Colombia, 24.8%; and Peru, 67.0%).3 
In this report, we update the frequency of EGFR and KRAS 
mutations in Latin America, including data from Costa Rica 
and Panama.
PATIENTS AND METHODS
Patient Selection
All Latin-American patients (1713 from Argentina, 
1417 from Mexico, 1939 from Colombia, 393 from Peru, 102 
from Costa Rica, and 174 from Panama) exhibited histologi-
cally confirmed lung cancer. Brazil presented independently 
their results in Latin American Lung Cancer Conference 
2014.12 The protocol was approved by a central ethical and sci-
entific committee in the National Cancer Institute in Mexico 
City (approval number 011/012/ICI, CB/678, “Frecuencia de 
Mutaciones, en el Gen del Receptor del Factor de Crecimiento 
Epidérmico, EGFR, en Latinos/Hispanos con Cáncer de 
Pulmón de Células No Pequeñas”). Informed consent autho-
rizing implementation of detecting mutations of EGFR and 
Kras was independent for each country and in accordance with 
the provisions and guidelines of each institution. The analysis 
included patients from our previous report (1150 patients).3
Tissue Procurement
Biopsies were taken using transbronchial sampling, tho-
racoscopic segmental resections, or computed tomography-
guided core needle biopsy and were analyzed by the pathology 
departments of the different participating institutions for their 
histological diagnosis and quantification of neoplastic cellular-
ity (>50%). The sections were later embedded in paraffin until 
processing for DNA extraction. Genomic DNA was extracted 
by a standard procedure from areas of the paraffin slides 
using the QIAamp DNAFFPE Tissue Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions.
Mutational Analysis
Direct sequencing in patients from Argentina, 
Colombia, Peru, and Costa Rica was performed at each site. 
The kinase domain of EGFR was amplified by polymerase 
chain reaction (PCR). Two separate PCR reactions, each with 
the corresponding pair of primers, were used to amplify exon 
19 (FWD 5′GCAATATCAGCCTTAGGTGCGGCTC3′ and 
RVS 5′CATAGAAAGTGAACATTTAGGATGTG3′) and 
exon 21 (FWD 5′CTAACGTTCGCCAGCCATAAGTCC3′ 
and RVS 5′GCTGCGAGCTCACCCAGAATGTCTGG3′) 
of the EGFR gene. Codons 12 and 13 of KRAS 
were amplified by PCR with specific primers (FWD 
5′GGAGAGAGGCCTGCTGAAAATGAC3′ and RVS 
5′TTGCTTCCTGTAGGAATCCTCTA3′). These PCR prod-
ucts were then subjected to direct sequencing using the same 
primers, and all mutations were confirmed by bidirectional 
sequencing originating from both the upstream and downstream 
primers. In México and Panama, mutations of the EGFR (exons 
18, 19, 20, and 21) and KRAS genes were detected using the 
therascreen RGQ PCR Kit (QIAGEN, Scorpions amplification 
refractory mutation system [ARMS] method), which combines 
two technologies, namely the ARMS and quencher-tailed fluo-
rescent primers or Scorpions, to detect mutations in real-time 
PCR reactions. Real-time PCR was performed using a Rotor-
Gene Q 5plex HRM (QIAGEN) according to the manufac-
turer’s instructions.13,14 A similar procedure was performed in 
75% of samples from Colombia using the cobas real-time PCR 
platform (Roche, Bogota, Columbia).
Statistical Analysis
For descriptive purposes, continuous variables were 
summarized as arithmetic means, medians, and standard devi-
ations, and categorical variables were reported as proportions 
with 95% confidence intervals (95% CI). Inferential compari-
sons were performed using Student’s t test. The χ2 or Fisher’s 
exact tests were used to assess significance among categorical 
variables. Statistical significance was determined as p ≤ 0.05 
with a two-sided test. Statistically significant and borderline 
significant variables (p < 0.1) were included in multivariate 
logistic regression analysis included the different countries. 
Progression-free survival and overall survival were measured 
from the day of EGFR TKI treatment to the date of progres-
sion or death and analyzed with the Kaplan Meier technique, 
whereas comparisons among subgroups were performed with 
the log-rank test.
RESULTS
The median age of all patients was 62.2 ± 12.3; 53.5% 
were women and 95.2% had adenocarcinoma histology. Of all 
patients, 46.7% had a history of smoking. With regard to eth-
nicity, 49% were self-reported Caucasian patients, and 50.8% 
were self-reported mestizo/indigenous ancestry (Table 1).
Molecular Genotyping of Patients
Among all patients, the frequency of EGFR mutations 
in NSCLC was 26.0% (95% CI, 23.8–28.2; Argentina, 14.4% 
[12.8–15.6]; México, 34.3% [31.9–36.7]; Colombia, 24.7% 
[22.8–26.6]; Peru, 51.1% [46.2–55.9]; Panamá, 27.3 [20.7–
33.9]; and Costa Rica, 31.4% [22.4–40.4]).The frequency of 
KRAS mutations was 14.0% (9.1–14.9). The most frequent 
EGFR mutations were deletions in exon 19, 47.1%, followed 
by L858R in 37.3%. The basal T790M mutation was detected 
in 5.8% of EGFR-mutated NSCLCs; however, only 1.4% of all 
genotyped NSCLCs exhibited this mutation. We cannot assess 
whether these detected T790M mutations are associated with 
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clinical EGFR-TKI resistance. In patients harboring EGFR 
mutations, other less common mutations were reported in 
exon 18 (87 of 1124 patients, 7.7%), insertions in exon 20 (4 
of 128 patients, 3.1%), in exon 20 S768I mutation (33 of 824 
patients, 4.0%), in exon 21 L8161Q (6 of 468 patients, 1.3%), 
in exon 20 R831H (2 of 506 patients, 0.4%), and some point 
mutations in exon 21, T7847A, V834A, L858A, and L861G, 4 
of 4768, 0.2% each one (Supplement 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A795).
Clinical and Pathological Characteristics 
Associated with EGFR Mutations in Patients 
with Only Adenocarcinoma Histology
The frequency of the EGFR mutations in adenocar-
cinoma patients was 26.4%. EGFR mutations were associ-
ated with gender (30.7% in females vs. 18.4% in males; 
p < 0.001), self-reported nonsmoker status (27.4% vs. 17.1%; 
p < 0.001), self-reported ethnicity (mestizo/indigenous, 
35.3% and Caucasian, 13.7%; p < 0.001), and the absence of 
KRAS mutation (38.1% vs. 4.7%, p < 0.001; Table 2). In the 
multivariate analysis, all these factors were associated (gender 
hazard ratio, 0.45 [95% CI, 0.36–0.56]; smoking history, 0.68 
[0.550.83]; KRAS, 0.14 [0.060.35]; ethnicity, 0.47 [0.38 – 0.57], 
p < 0.001). However, multivariate logistic regression (includ-
ing Countries/Regions) identified gender (p < 0.001), smoking 
history (p < 0.001), and regions (p < 0.001) to be indepen-
dent predicted factor to EGFR mutation status (Supplement 
2, Supplemental Digital Content 2, http://links.lww.com/JTO/
A796).
Response to EGFR TKIs
Complete outcome information regarding EGFR TKI 
treatment was only available for 328 patients. The over-
all response rate in patients with EGFR-mutated NSCLC 
(n = 109) was 60.6% (95% CI, 52.10–69.09), with a progres-
sion-free survival of 15.9 months (95% CI, 12.4–20.6) and 
a median overall survival of 32 months (95% CI, 12.4–20.6; 
Fig. 1A and B). The overall response rate to EGFR TKIs for 
white/Caucasian was 58.3% (95% CI, 42.4–74.2) versus 
65.5% (52.9–78.1) for mestizo/indigenous in patients with 
EGFR Mutations (p = 0.492).
DISCUSSION
We have demonstrated that a very significant proportion 
of NSCLCs from patients from Latin America with a Hispanic 
background harbor EGFR activating mutations and therefore 
constitute an important and very well-defined subgroup of 
patients with lung cancer. This information is important for 
both Latin-American countries and the United States; 16.3% 
of the US population is of Hispanic origin, and this proportion 
TABLE 1.  Demographic and Clinical Characteristics of All Patients
Variable Argentina, N (%) México, N (%) Colombia, N (%) Perú, N (%) Costa Rica, N (%) Panamá, N (%) Total
Number of patients 1713 (29.9) 1417 (24.7) 1939 (33.8) 393 (6.8) 102 (1.8) 174 (3.0) 5738
Mean age ± SD 63.5 ± 10.5 60.5 ± 12.8 61.5 ± 13.6 65.9 ± 15 63.9 ± 12.6 62.2 ± 12.3
Gender
  Female (%) 748 (43.7) 505 (52.4) 1228 (63.3) 99 (48.8) 60 (58.8) 87 (50) 2727 (53.5)
  Male (%) 965 (56.3) 458 (47.6) 711 (36.7) 104 (51.2) 42 (41.2) 87 (50) 2367 (46.5)
Histology
  Adenocarcinoma (%) 1713 (100) 1287 (90.8) 1807 (93.2) 203 (100) 97 (96.0) 162 (93.1) 5461 (95.2)
  LCC (%) 0 (0) 8 (0.6) 7 (0.4) 0 (0) 1 (1.0) 1 (0.6) 17 (0.3)
  NOS/ND (%) 0 (0) 30 (2.1) 84 (4.3) 0 (0) 2 (2.0) 6 (3.4) 122 (2.1)
  SCC (%) 0 (0) 92 (6.5) 41 (2.1) 0 (0) 1 (1.0) 5 (2.9) 138 (2.4)
Smoking status
  Smokera (%) 1184 (69.7) 242 (47.5) 467 (24.8) 61 (59.8) 75 (47.8) 2036 (46.7)
  Never smokerb (%) 514 (30.3) 275 (52.5) 1416 (75.2) 41 (40.2) 82 (52.2) 2328 (53.3)
Ethnicity
  Caucasian (%) 1713 (100) 6 (0.5) 355 (36.2) 6 (3.0) 1977 (49)
  Mestizo/Indigenous (%) 0 (0) 1228 (99.5) 619 (63.1) 197 (97.0) 2052 (50.8)
  Asian (%) 0 (0) 1 (0.1) 0 (0) 0 (0) 1 (0.0002)
  African Americans (%) 0 (0) 0 (0) 7 (0.7) 0 (0) 7 (0.2)
EGFR sensitizing mutation status
  Positive (%) 247 (14.4) 486 (34.3) 479 (24.7) 201 (51.1) 32 (31.4) 47 (27.3) 1491 (26.0)
  Negative (%) 1466 (85.6) 931 (65.7) 1460 (75.3) 192 (48.9) 70 (68.6) 125 (72.7) 4247 (74.0)
KRAS
  Positive (%) 40 (15.9) 116 (12.9) 34 (16.8) 190 (14.0)
  Negative (%) 210 (84.1) 785 (87.1) 168 (83.2) 1165 (86.0)
aPatients who have smoked more than 100 cigarettes in their lifetime.
bPatients who had never smoked cigarettes in their lifetime.
LCC, large cells cancer; ND, undifferentiated; NOS, not otherwise specified; SCC, squamous cells cancer.
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is expected to increase in the coming years.15 These differ-
ences could be partially explained by different genetic suscep-
tibilities and exposure to several specific risk factors, such as 
wood smoke exposure (WSE). The problem of WSE is nearly 
exclusive to developing countries, and although not very 
well studied, it is estimated that up to 16% of households use 
wood as fuel for heating and cooking in some parts of Latin 
America.2 It has been observed that WSE is an independent 
factor for increased EGFR mutation frequency and decreased 
KRAS mutation frequency.16,17 The evident differences in 
the frequencies of EGFR mutations between the Caucasian 
and Asian populations are also present in other populations, 
including Turkey (42%),18 India (33.3%),19 Brazil (25.3%),20 
and Chile (22%),21 where it appears to exist in an intermediate 
frequency between both populations.
Brazil recently published two abstracts evaluating the 
frequency of EGFR mutations in their population. In both 
abstracts, the reported EGFR mutation frequency was similar: 
25.9% (847 of 3364)22 and 27% (66 of 304; in these reports 
the detection of EGFR mutation was performed, in most 
cases using the Sanger sequencing). These results are compa-
rable with those obtained by our analysis in the rest of Latin 
America.12
In our study, we observed an important heterogeneity 
in Latin America; as with previous studies, there was a strong 
positive relationship with female sex and negative relation-
ship with the degree of tobacco exposure. Multivariate logistic 
analyses indicated a wide difference in mutation frequency 
by country/ethnicity regarding gender and smoking history 
(Supplement 2, Supplemental Digital Content 2, http://links.
lww.com/JTO/A796). The EGFR mutation frequency was 
higher in Peru and lower in Argentina. Importantly, Peru has 
been a destination of Asian migration, whereas in Argentina, 
the majority of the population is of Caucasian origin. These 
findings suggest that lifestyle and genetics (smoking exposure 
history) and ethnicity are important in determining mutation 
frequency. Several reports show that polymorphism frequen-
cies within EGFR gene are also influenced by smoke expo-
sure and ethnicity.23,24 Despite the high frequency of EGFR 
mutation in Asia, there is an important ethical heterogeneity 
manner similar to our study, there are differences in EGFR fre-
quency in the mutation according to the country or regions.25
Another important difference in the Latin American 
population is the low frequency of KRAS mutation that could 
be explained by a lower frequency of smokers in our cohort 
and a high EGFR mutation frequency, which are mutually 
exclusive.26 Previously, we have demonstrated that in patients 
with KRAS-mutated NSCLC, the response to treatment with 
chemotherapy and EGFR TKI is lower, which negatively 
impacts the overall survival.26 Although, a recent report 
describes that the frequency of EGFR mutations is similar 
in US Hispanics compared with non-Hispanic whites.27 This 
suggests important influence of lifestyle in EGFR mutation. 
Patel et al.28 demonstrated that foreign-born Hispanic patients 
with NSCLC exhibited higher survival compared with non-
Hispanic whites and US-born Hispanics. This observation 
could be explained by the high frequency of the EGFR muta-
tion and the low frequency of the KRAS mutation in the 
Hispanic population. Recently, it was reported that several 
baseline clinical features (female sex, Asian or Hispanic eth-
nicity, lower stage, etc.) were independently associated with 
the frequency of mutation, which improved the cause-specific 
survival in patients <50 years of age. However, it appears that 
there are differences not only in molecular profiling but also 
in histological features. Hispanic patients diagnosed with 
NSCLC have a higher proportion of histologically favorable 
tumors, which are associated with improved survival in this 
population.29 A limitation of our study was that the muta-
tions were detected by two different methods (ARMS and 
Sequencing). However, standard to define the optimal testing 
method and specimen type required for the detection of EGFR 
mutations is not available. Some studies suggest that EGFR 
mutations are less detected in small biopsies from bronchos-
copy regardless of the method used and where there is more 
tissue, and laboratory tests may be based on the experience 
of the laboratory but direct sequencing is highly recom-
mended.30 In other study, the sensitivity of direct sequencing 
and ARMS was 44.1% and 94.1%, respectively, for biopsy 
tumor tissues, but for surgery samples, sensitivity of direct 
sequencing and ARMS was 72.2% and 94.4%, respectively; 
ARMS has a higher sensitivity, and specific that sequencing of 
detection of EGFR mutation, and some report that the results 
for ARMS are more consistent with the efficacy of EGFR 
treatment.31,32 Other important limitation is that our study is a 
retrospective cohort, and this leads to incomplete data about 
TABLE 2.   EGFR Mutation Frequency for Demographic and 
Clinical Characteristic Subgroups
N
EGFR Mutation
PFrequency (%) 95% CI
Country/Region
  Argentina 1713 247 (14.4 12.8–15.6
  Mexico 1417 472 (36.7 34.4–39.6
  Colombia 1939 456 (25.2 23.2–27.2
  Peru 393 201 (51.1 46.2–55.9
  Panama 174 41 (25.5 21.8–29.2
  Costa Rica 102 32 (32.7 23.4–41.9 <0.001
Gender
  Female 2589 794 (30.7) 29–32.4
  Male 2228 410 (18.4) 16.8–20 <0.001
Age
  ≤60 1817 417 (22.9) 21–24.8
  >60 2567 592 (22.8) 21.6–24.6 0.757
Ethnic group
  Mestizo/indigenous 1891 668 (35.3) 33.2–37.5
  Caucasian 1942 267 (13.7) 12.2–15.3
  African Americans 6 0 <0.001
Smoking status
  Smoking 1953 333 (17.1) 15.4–18.7
  Never smoking 2188 600 (27.4) 25.4-29,3 <0.001
KRAS
  Positive 190 8 (4.7) 1.7–7.7
  Negative 1165 403 (38.1) 35.4–40.8 <0.001
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the demographic characteristics, and we have a tendency to 
include patients with high possibility to harbor EGFR muta-
tion, particular in Colombia and Peru.
In conclusion, this study represents the largest multi-
national effort to establish a genomic tumor profile in Latin 
America, which have a high frequency of EGFR mutations 
and a high variability in the frequency of EGFR mutation, 
and a low frequency of KRAS mutations compared with 
European/North American populations, possibly because 
of differences in ethnicity and other associated environ-
mental risk factors for lung cancer. Our findings support 
the genetic heterogeneity of NSCLC around the world by 
confirming that the frequency of EGFR mutations in Latin 
America is intermediate between that observed in the Asian 
and Caucasian populations.
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